Methods of using Zscan4 for rejuvenating human cells
AssigneeElixirgen Therapeutics, Inc.
InventorMinoru S.H. Ko
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.
Claims23
A method for rejuvenating one or more somatic cells of a human subject, comprising:
- contacting the somatic cells with an isolated nucleic acid molecule encoding human Zscan4 to increase expression of human Zscan4 protein to produce rejuvenated somatic cells,
- wherein the rejuvenated somatic cells have a higher population doubling capacity than somatic cells that were not contacted with the nucleic acid molecule.
A method of inducing expression of a Zscan4 marker gene in one or more human induced pluripotent stem (iPS) cells, comprising
- contacting the one or more human iPS cells with an agent that increases expression of a human Zscan4 protein in the one or more human iPS cells, wherein increased expression of the human Zscan4 protein induces expression of a Zscan4 marker gene in the one or more human iPS cells, wherein the Zscan4 marker gene comprises one or more of SERPINB4, DNMT3L, and DUX4, and wherein the agent is an isolated nucleic acid molecule encoding the human Zscan4 protein.
A recombinant paramyxovirus vector encoding a human Zscan4 protein.
A composition comprising a plurality of human induced pluripotent stem (iPS) cells and a synthetic mRNA encoding a human Zscan4 protein.
Dependencies are inferred from the claim text.